Icagen Reviews

0 Reviews
0 Reviews

Recommend to a friend
Approve of CEO
(no image)
P. Kay Wagoner
0 Ratings

Icagen Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.icagen.com
Headquarters Durham, NC
Size 16 to 50 Employees
Founded Unknown
Type Company - Private
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year

Icagen wants to set the market for ion channel modulators on fire. The development-stage biotech focuses on treatments for epilepsy, asthma, pain, and inflammation by regulating the inflow into cells of such ions as calcium, potassium, and sodium. Icagen's lead candidate, senicapoc for sickle cell disease, died in 2007 following lackluster Phase III clinical trial results. The drug was being developed in a partnership with Johnson & Johnson subsidiary McNeil Consumer & Specialty Pharmaceuticals. Shortly thereafter Icagen announced a deal collaborating with Pfizer on the... More

Work at Icagen? Share Your Experiences


Click to Rate